Literature DB >> 17497095

Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome.

Tanja Langsenlehner1, Claudia Stiegler, Franz Quehenberger, Günther C Feigl, Gabi Jakse, Michael Mokry, Uwe Langsenlehner, Karin S Kapp, Ramona Mayer.   

Abstract

PURPOSE: Evaluation of long-term tumor control, normalization of hormonal hypersecretion, including incidence and time course of pituitary dysfunction following postoperative radiotherapy of pituitary macroadenomas. PATIENTS AND METHODS: In a retrospective study, the data of 87 patients with pituitary macroadenomas (61 non-secreting adenomas, 26 secreting adenomas) treated between 1984 and 1994 were analyzed. All patients underwent surgery and received postoperative external-beam radiotherapy with a mean dose of 50.4 Gy (range 46-54 Gy).
RESULTS: After a follow-up of 15 years the local tumor control rate achieved was 93.0% for non-secreting adenomas and 100% for secreting adenomas, respectively. Normalization of endocrine hypersecretion was noted in 24 of 26 patients (92%). Detailed endocrinological follow-up data were analyzed by an experienced endocrinologist in 77 patients. After a median follow-up of 10.54 years (mean 10.22; range 1.39-20.75 years), in 75 of 77 patients (97%) a hypopituitarism was observed (partial hypopituitarism, n = 28 [36%], panhypopituitarism, n = 47 [61%]), and 68 out of 77 patients (88%) showed evidence of radiotherapy-induced pituitary disorders. The somatotropic function was most commonly affected, followed by gonadal, thyroid and adrenal function. The gonadal axis showed to be the first to be disturbed. 67 patients (87%) required a hormone replacement therapy.
CONCLUSION: Radiotherapy after pituitary surgery is highly effective in reducing hormonal hypersecretion and preventing recurrences of pituitary adenomas. However, pituitary insufficiencies are commonly observed after radiotherapy requiring a close follow-up to ensure timely diagnosis of pituitary dysfunction and an early inception of hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497095     DOI: 10.1007/s00066-007-1706-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  14 in total

1.  Influence of intravenous contrast agent on dose calculation in 3-D treatment planning for radiosurgery of cerebral arteriovenous malformations.

Authors:  Angelika Zabel-du Bois; Benjamin Ackermann; Henrik Hauswald; Oliver Schramm; Gabriele Sroka-Perez; Peter Huber; Jürgen Debus; Stefanie Milker-Zabel
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

Review 2.  [New aspects of tumor pathology of the pituitary].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

3.  Gamma Knife radiosurgery as the initial treatment for elderly patients with nonfunctioning pituitary adenomas.

Authors:  Lifeng Zhang; Wei Chen; Chang Ding; Yanjia Hu; Yuan Tian; Huiyang Luo; Jing Chen
Journal:  J Neurooncol       Date:  2021-02-27       Impact factor: 4.130

Review 4.  Epidemiology of Male Hypogonadism.

Authors:  Arthi Thirumalai; Bradley D Anawalt
Journal:  Endocrinol Metab Clin North Am       Date:  2022-02-08       Impact factor: 4.748

Review 5.  Management of nonfunctioning pituitary tumors: radiotherapy.

Authors:  Giuseppe Minniti; John Flickinger; Barbara Tolu; Sergio Paolini
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 6.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

7.  Combined radiotherapy and indomethacin for the prevention of heterotopic ossification after total hip arthroplasty.

Authors:  Emilios E Pakos; Kosmas S Stafilas; Pericles G Tsekeris; Aggelos N Politis; Gregory Mitsionis; Theodore A Xenakis
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

8.  Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Authors:  I Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid A Siddiqui; Danilo Silva; Mayur Sharma; Hesham Radwan; Jonathan A Cohen; Robert F Dallapiazza; Christian Iorio-Morin; Amparo Wolf; John A Jane; Inga S Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Chih-Chun Wu; Christopher P Cifarelli; Tomas Chytka; Gene H Barnett; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurosurg       Date:  2017-10-27       Impact factor: 5.115

9.  Endocrine sequelae of cancer and cancer treatments.

Authors:  Charles J Stava; Camilo Jimenez; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2007-11-20       Impact factor: 4.442

10.  Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas.

Authors:  Stefan Rieken; Daniel Habermehl; Thomas Welzel; Angela Mohr; Katja Lindel; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2013-01-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.